ArriVent BioPharma, Inc.

NasdaqGM:AVBP Stock Report

Market Cap: US$1.4b

ArriVent BioPharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Bing Yao

Chief executive officer

US$9.4m

Total compensation

CEO salary percentage6.37%
CEO tenure5yrs
CEO ownership0.5%
Management average tenure2.8yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

Seeking Alpha • Apr 29

ArriVent BioPharma: A First Assessment

Summary ArriVent BioPharma (AVBP) is advancing firmonertinib for EGFR mutant NSCLC, targeting underserved Exon 20 and PACC mutations. AVBP awaits pivotal FURVENT trial data in mid-2026; positive results are critical, with market opportunity estimated just under $1 billion for Exon 20 globally. Competitive risk has increased following Dizal’s Zegfrovy Phase 3 success in the same indication, though detailed efficacy data remain undisclosed. A first assessment around ArriVent BioPharma follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Nov 13

Here's Why We're Watching ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • May 21

Is ArriVent BioPharma (NASDAQ:AVBP) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jan 11

We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 24

We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Sep 17

ArriVent BioPharma: Bringing A Novel Cancer Drug From China

Summary ArriVent BioPharma's lead molecule, firmonertinib, targets NSCLC with EGFR Exon 20 insertion mutations and shows potential in both classical and nonstandard EGFR mutations. Firmonertinib has demonstrated superior efficacy over first-generation TKIs and can cross the blood-brain barrier, showing promise for patients with brain metastases. With a market cap of $798mn and a cash balance sufficient for over 10 quarters, ArriVent is financially stable to continue its development. Upcoming catalysts include topline data from the phase 3 FURVENT trial in 2025, making firmonertinib a molecule worth watching in the nonstandard EGFRm space. Read the full article on Seeking Alpha
Seeking Alpha • Jan 29

ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment

Summary ArriVent raised $150 million in an upsized IPO, marking one of the strongest performances for a China-linked IPO in New York over the last two years. The company has licensed global rights, excluding Greater China, to furmonertinib, a highly targeted drug used to treat non-small-cell lung cancer. In addition to furmonertinib, the company also has another cancer drug in its pipeline that it is co-developing with Aarvik, though that one is at a far earlier stage in its development. In terms of valuation, ArriVent should probably be ultimately valued at similar levels to Allist, which currently trades at a strong P/S multiple of 5 and an equally strong P/E ratio of 38. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Bing Yao's remuneration changed compared to ArriVent BioPharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$145m

Dec 31 2025US$9mUS$597k

-US$166m

Sep 30 2025n/an/a

-US$151m

Jun 30 2025n/an/a

-US$137m

Mar 31 2025n/an/a

-US$127m

Dec 31 2024US$2mUS$558k

-US$80m

Sep 30 2024n/an/a

-US$81m

Jun 30 2024n/an/a

-US$75m

Mar 31 2024n/an/a

-US$75m

Dec 31 2023US$1mUS$536k

-US$69m

Sep 30 2023n/an/a

-US$59m

Jun 30 2023n/an/a

-US$56m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$1mUS$516k

-US$37m

Compensation vs Market: Bing's total compensation ($USD9.37M) is above average for companies of similar size in the US market ($USD5.26M).

Compensation vs Earnings: Bing's compensation has increased whilst the company is unprofitable.

CEO

Bing Yao (60 yo)

5yrs
Tenure
US$9,374,153
Compensation

Dr. Zhengbin Yao, also known as Bing, Ph D., is Member of Scientific Advisory Board of Shanghai Allist Pharmaceuticals Co. Ltd. Dr. Yao serves as Independent Non-Executive Director at VISEN Pharmaceuticals...

Leadership Team

NamePositionTenureCompensationOwnership
Zhengbin Yao
Co-Founder5yrsUS$9.37m0.47%
$ 6.7m
Stuart Lutzker
Co-Founderno dataUS$3.43m0.32%
$ 4.5m
Winston Kung
CFO & Treasurer2.4yrsUS$3.41m0%
$ 0
Robin LaChapelle
Co-Founder & COO2.8yrsUS$960.99k1.14%
$ 16.2m
Yang Wang
Chief Technology Officerno datano datano data
James Kastenmayer
General Counsel & Secretary2.8yrsno datano data
Brent Rice
Chief Commercial Officerless than a yearno datano data
2.8yrs
Average Tenure
57yo
Average Age

Experienced Management: AVBP's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Zhengbin Yao
Co-Founder5yrsUS$9.37m0.47%
$ 6.7m
Stuart Lutzker
Co-Founder5yrsUS$3.43m0.32%
$ 4.5m
James Healy
Independent Director3.3yrsno datano data
Kristine Peterson
Lead Independent Director1.4yrsUS$384.28k0%
$ 0
Merdad Parsey
Independent Director1.2yrsUS$509.12kno data
John Hohneker
Independent Director2.1yrsUS$356.15k0%
$ 0
Christian Nolet
Independent Director2.8yrsUS$366.78k0%
$ 0
2.8yrs
Average Tenure
65yo
Average Age

Experienced Board: AVBP's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 06:59
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ArriVent BioPharma, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
Mayank MamtaniB. Riley Securities, Inc.
Suranjit MukherjeeBTIG